223418-75-5

Usage

Uses

Used in Organic Synthesis:
2-Methyl-5-(tributylstannyl)thiazole is utilized as a key intermediate in organic synthesis for the preparation of a variety of complex organic molecules. Its tributylstannyl group facilitates easy replacement with other functional groups, making it a versatile component in the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Antimicrobial Applications:
2-Methyl-5-(tributylstannyl)thiazole is studied for its potential use as an antimicrobial agent. Its unique structure and properties are being investigated for their ability to combat various types of microorganisms, which could be beneficial in the development of new antimicrobial drugs and treatments.
Used in Chemical Research:
In the field of chemical research, 2-Methyl-5-(tributylstannyl)thiazole serves as a model compound for studying the reactivity and properties of organotin compounds. Its use in research contributes to a deeper understanding of the mechanisms and applications of organotin chemistry, which can lead to the discovery of new synthetic methods and applications in various industries.

InChI:InChI=1/C4H4NS.2C4H9.C3H7.Sn/c1-4-5-2-3-6-4;2*1-3-4-2;1-3-2;/h2H,1H3;2*1,3-4H2,2H3;1,3H2,2H3;/rC15H29NSSn/c1-5-8-11-18(10-7-3,12-9-6-2)15-13-16-14(4)17-15/h13H,5-12H2,1-4H3

Upstream product

• 3581-87-1 2-methylthiazole 
• 1461-22-9 tributyltin chloride 

Downstream Products

• 1425042-32-5 C₂₆H₂₁N₇OS 
• 1420620-37-6 C₂₈H₂₃N₇OS 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS

Aminopyrazine compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology.

INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF

The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.

1,2,4-TRIAZOL-5-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES

Described are compounds of Formula I which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-lR), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-FMS, c-KIT, or PDGFR kinases.

IMIDAZOLIDINONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES

Described are compounds of Formula I which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-1R), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-FMS, c-KIT, or PDGFR kinases.

8-ETHYL-6-(ARYL)PYRIDO [2,3-D]PYRIMIDIN-7(8H) -ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER

Provided herein are PAK inhibitors and methods of utilizing PAK inhibitors for the treatment of CNS disorders such as neuropsychiatric disorders or neurofibromatosis. Also described herein are methods of utilizing PAK inhibitors for the treatment of cancer.

FUSED HETEROAROMATIC PYRROLIDINONES

Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, L1, L2, R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of SYK is indicated.